U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07206277) titled 'Fibroscan to Guide Post Transplant Immunosuppression Minimization' on Sept. 25.
Brief Summary: Following Liver transplantation, recipients remain on life long immunosuppression. Prolonged exposure to immunosuppression is associated with side effects and complications including kidney dysfunction, diabetes, heart disease and cancer risk.
Therefore studies are looking at safe ways to reduce or stop immunosuppression. An individual without autoimmune liver disease (these patients are at higher risk of rejection), without history of rejection, with normal blood tests (liver biochemistry, liver function, etc.) can be eligible for minimiz...